Intended for healthcare professionals


GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm

BMJ 2023; 383 doi: (Published 08 December 2023) Cite this as: BMJ 2023;383:p2906
  1. Deborah Cohen
  1. London

The European Medicines Agency (EMA) has asked some licence holders of GLP-1 receptor agonists for evidence into associations with suicidal ideation and self-harm as part of a review. These drugs include Ozempic (semaglutide), Saxenda (liraglutide), and Wegovy (semaglutide) and are used to treat type 2 diabetes and in weight management.

The review was triggered by the Icelandic Medicines Agency in July after reports of suicidal thoughts and self-injury in people using liraglutide and semaglutide. The authorities have so far retrieved and analysed about 150 reports of possible cases of self-injury and suicidal thoughts.

The EMA’s …

View Full Text

Log in

Log in through your institution


* For online subscription